Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-07260437 |
| Synonyms | |
| Therapy Description |
PF-07260437 is a bispecific antibody targeting B7H4 and CD3, which potentially activates a cytotoxic T-cell response against tumor cells expressing B7H4 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-07260437 | PF 07260437|PF07260437 | CD3 Antibody 119 | PF-07260437 is a bispecific antibody targeting B7H4 and CD3, which potentially activates a cytotoxic T-cell response against tumor cells expressing B7H4 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Terminated | USA | 1 |